Stockpicks
SNMP BUY/LONG NOW READY 0.55 to 2.95 by end 2021 LAST CALLTICKER CODE: SNMP
Company Name: Evolve Transition Infrastructure LP
Industry: Energy | Oil & Gas Midstream | USA
Position Proposed: BUY
Entry: NOW READY (0.55-0.65)
RE-ENTRY: 0.720 - 0.740
1st Partial Take Profit: 2.14 (July-October 2021)
2nd Partial Take Profit: 2.95 (End 2021)
3rd Take Profi: 3.75 (Mid 2022)
Technical Analysis
1. Large Inverted Head & Shoulders (Forming)
2. Falling Wedge / Pennant (Forming)
3. Fibonacci Retracement at 0.786 ( Silver Zone)
4. 1st Take Profit will be at Fibonacci Expansion Safe Take Profit and Flagpole Length
5. 2nd Take Profit would be somewhere near Key Structure Level (Very likely for price rejection/Pullback)
6. 3rd Take Profit at Inverted Head & Shoulders Breakout Take Profit Price Range of Head
Global Trade Analysis for Tenneco, IncOur Global Algorithmic Trading Software (GATS) #7 indicates the following for Tenneco, Inc.
The Long Term Trend (LTT) is currently Bullish
The Medium Term Trend (MTT) is currently Bullish
The Short Term Trend (STT) is currently Bullish
The Micro Trend (MT) is currently Bullish
Global Entry Signal For Trade #1: $12.38
Global Current Trailing Stop Distance For Trade #1: $14.84
Global Target Profit Trade #1 : $30.00
RISK WARNING!
There is a substantial risk of loss in futures and Forex trading. Online trading of stocks and options is extremely risky. Assume you will lose money. Don’t trade with money you cannot afford to lose.
The analysis in this material is provided for information only and is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security.
To the extent that this material discusses general market activity, industry or sector trends or other broad-based economic or political conditions, it should not be construed as research or investment advice.
To the extent that it includes references to specific securities, commodities , currencies, or other instruments, those references do not constitute a recommendation by Global Accountancy Institute,Inc. or Global Financial Engineering,Inc. to buy, sell or hold such investments.
This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers.
Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
✅↗️ BIG BREAKOUT SOON🔜✅✅↗️ BIG BREAKOUT SOON🔜✅
- STOCK NAME : ELECON ENGINEERING
- SCRIP : NSE: ELECON
- INDUSTRY : EQUIPMENTS
- LTP : 111.70
- ✅TECHNICAL ANALYSIS DETAILS✅
1. PRICE COMING OUT OF 13 YEAR LONG CONSOLIDATION PERIOD .✅
2. RECENT VOLUME BUILD UP.✅
3. MACD BULLISH CROSSOVER.✅
4. MONTHLY CLOSE ABOVE 114 CAN BE BULLISH SIGNAL. ✅
5.RSI LEVEL IS ALSO STRONG.✅
6. BREAKOUT LEVEL - 114.✅
NOTE❗ : AFTER BREAKOUT PRICE MAY CONSOLIDATE A LITTLE BIT AFTER A LONG REALLY & RETEST ON BREAKOUT LEVEL ACTING AS SUPPORT.
🚫This is only for Educational Purpose 🚫
➡️Consult Your Financial Advisors Before Taking Any Trade💻
An Upward correction on SolarEdge SEDG
SEDG is showing a room from an upside move inside the downward channel after retreating from the lower boundary of it.
Prices could target $260 and $273.25 respectively.
Long Carnival CCLCarnival stock CCL is trading above its exponential moving averages after finding a support at $24.30.
CCL violated the downward trend line upwardly in an attempt from the bulls to take control over prices.
Sellers tested the violated trend line, then prices retread from it opening the door for targeting $29.90.
Microsoft MSFT bullish triggerMicrosoft MSFT is showing a bullish price action on the daily time frame.
Prices could move higher from the current prices to fill the downward gap around $258.60.
Mastercard MA Buy Zone
Mastercard MA is still moving higher with the a significant bullishness recently appeared in violating the resistance around $368.65.
The RSI and momentum indicators are supporting more upside potential hitting $383 and $395.70 consecutively.
Atreca Inc - It's time to load up. 🧙Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.
-20%
If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
RIOT BUY/LONG BIG OPPORTUNITY! 15 to 97 by end 2021! TICKER CODE: RIOT
Company Name: Riot Blockchain, Inc.
Industry: Technology | Software - Application | USA
Position Proposed: BUY
Technical Analysis
1. Flag Pattern (Forming)
2. Fibonacci Retracement at 0.786 ( Silver Zone)
3. 1st Partial Take Profit will be at Fibonacci Expansion Safe Take Profit, Flagpole Length and somewhere near Key Structure Level (Very likely for price rejection/Pullback)
4. 2nd Partial Take Profit would be somewhere near the Next Key Structure Level (The Market will very likely reach this point before having a major rejection again)
Entry: NOW READY (15.00-26.00) - The Market could fall below 26.00 again but very unlikely
1st Partial Take Profit: 97.00 (October - End 2021)
2nd Partial Take Profit: 2.95 (End 2021)
3rd Take Profi: 3.75 (Mid-End 2022)
Note that in the Monthly chart timeframe the market is creating a large inverted Head & Shoulders, as such I will still hold some of this stock on hand. Should the market break beyond 145, the next take profit will be at roughly 200-250 price range.
ACADIA Pharmaceuticals Inc 🧙Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NNOX, Ready for Round #4?I think Nanox has been heavily shortened on FDA news, which isn't surprising knowing the market's tricks. That said, it is accumulating and has been around the $33 price point for the past few days. I think now is the time where for the next few weeks, support levels can start picking up. It does have potential for a next wave bull run at these levels, and a real short squeeze is yet to happen in my opinion. That said, everything I say is on an opinion based basis. Invest at your own risk and do your own due diligence.
Playboy PLBY is a Multi-BaggerThis is not my idea or research. This is an idea from one of my favorite analysts, Brian McGough, who is a retail director at Hedgeye Risk Management. He said GME GameStop was a potential 10-bagger when it was at $20 late last year, and he's recently said he thinks PlayBoy is a 10-bagger (from ~$20). The general thesis is that the old management is gone and new management will have an opportunity to pivot the company towards a global sex, health, and media market that has a size of something like 300 billion. Still great upside from here, I am long the stock from $40 and am buying every dip.
NFLX is in lower lever of a trending channelNFLX could continue the uptrend of the channel that has formed through the last months.
Target Price: 590
Disney is consolidatingDisney is forming an accumulation pattern, Support level has been tested in the past 4 times.
Target price: 200
$ENTX PT 6-10 and higherEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Annexon Inc long scenario 🧙Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
$PVDG UptendingPVDG Watch out of the gates at open as it may have a slight pullback from last trading day.
PLTR in a KEY SUPPORT areaPLTR is testing again the strong support area, already 4 bounce.
Target Price: 35
DAL is on the support level of a consolidationDAL is on the support level tested several times in the consolidation
Target price: 51
Facebook is retracing of a breakout of a consolidation periodFacebook is ready to bounce hard after a pullback to the resistance level of the previous consolidation period.
Target Price: 330
